The clinically available NMDA receptor antagonist, memantine, exhibits relative safety in the developing rat brain

International Journal of Developmental Neuroscience

Volumn 29, Issue 7, 2011, Pages 767-773

  Manning, Simon M ^a,b   Boll, Griffin ^a   Fitzgerald, Erin ^a   Selip, Debra B ^a   Volpe, Joseph J ^a   Jensen, Frances E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Apoptosis; Development; Memantine; NMDA receptor; Periventricular leukomalacia; Synapses

Indexed keywords

AMPA RECEPTOR; DIZOCILPINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPSIN I;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DEVELOPMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; LOADING DRUG DOSE; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; SYNAPTOGENESIS;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BRAIN; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; IN SITU NICK-END LABELING; INFANT, NEWBORN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOMALACIA, PERIVENTRICULAR; MALE; MEMANTINE; MEMBRANE PROTEINS; NEUROPROTECTIVE AGENTS; PROTEIN SUBUNITS; RATS; RATS, LONG-EVANS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSINS;

ANIMALIA; RATTUS;

EID: 80053569853     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2011.05.005     Document Type: Article

References (42)

1. Bittigau P., Sifringer M., Genz K., Reith E., Pospischil D., Govindarajalu S., Dzietko M., Pesditschek S., Mai I., Dikranian K., Olney J.W., Ikonomidou C. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc. Natl. Acad. Sci U.S.A. 2002, 99:15089-15094.
2. Bormann J. Memantine is a potent blocker of N-methyl-d-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 1989, 166(3):591-592.
3. Brambrink A.M., Evers A.S., Avidan M.S., Farber N.B., Smith D.J., Zhang X., Dissen G.A., Creeley C.E., Olney J.W. Isoflurane-induced neuroapoptosis in the neonatal rhesus macaque brain. Anesthesiology 2010, 112:834-841.
4. Chen H.S., Pellegrini J.W., Aggarwal S.K., Lei S.Z., Warach S., Jensen F.E., Lipton S.A. Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 1992, 12:4427-4436.
5. Chen H.S., Wang Y.F., Rayudu P.V., Edgecomb P., Neill J.C., Segal M.M., Lipton S.A., Jensen F.E. Neuroprotective concentrations of the N-methyl-d-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 1998, 86:1121-1132.
6. Chez M.G., Burton Q., Dowling T., Chang M., Khanna P., Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J. Child Neurol. 2007, 22:574-579.
7. Cho K.K., Khibnik L., Philpot B.D., Bear M.F. The ratio of NR2A/B NMDA receptor subunits determines the qualities of ocular dominance plasticity in visual cortex. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:5377-5382.
8. Dobbing J., Sands J. Quantitative growth and development of human brain. Arch. Dis. Child. 1973, 48:757-767.
9. Fagiolini M., Katagiri H., Miyamoto H., Mori H., Grant S.G., Mishina M., Hensch T.K. Separable features of visual cortical plasticity revealed by N-methyl-d-aspartate receptor 2A signaling. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2854-2859.
10. Follett P.L., Rosenberg P.A., Volpe J.J., Jensen F.E. NBQX attenuates excitotoxic injury in developing white matter. J. Neurosci. 2000, 20:9235-9241.
11. Forest Pharmaceuticals Inc Namenda Package Insert 2003, Forest Pharmaceuticals Inc, St. Louis, MO.
12. Hall B.J., Ripley B., Ghosh A. NR2B signaling regulates the development of synaptic AMPA receptor current. J. Neurosci. 2007, 27:13446-13456.
13. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Tenkova T., Stefovska V., Turski L., Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999, 283:70-74.
14. Istaphanous G.K., Loepke A.W. General anesthetics and the developing brain. Curr. Opin. Anaesthesiol. 2009, 22:368-373.
15. Jantas-Skotniczna D., Kajta M., Lason W. Memantine attenuates staurosporine-induced activation of caspase-3 and LDH release in mouse primary neuronal cultures. Brain Res. 2006, 1069:145-153.
16. Jantas D., Lason W. Protective effect of memantine against Doxorubicin toxicity in primary neuronal cell cultures: influence a development stage. Neurotox. Res. 2009, 15:24-37.
17. Jantas D., Pytel M., Mozrzymas J.W., Leskiewicz M., Regulska M., Antkiewicz-Michaluk L., Lason W. The attenuating effect of memantine on staurosporine-, salsolinol- and doxorubicin-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem. Int. 2008, 52:864-877.
18. Johnson S.A., Young C., Olney J.W. Isoflurane-induced neuroapoptosis in the developing brain of nonhypoglycemic mice. J. Neurosurg. Anesthesiol. 2008, 20:21-28.
19. Lipton S.A. Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 2007, 8:803-808.
20. Liu C., Lin N., Wu B., Qiu Y. Neuroprotective effect of memantine combined with topiramate in hypoxic-ischemic brain injury. Brain Res. 2009, 1282:173-182.
21. Manning S.M., Talos D.M., Zhou C., Selip D.B., Park H.K., Park C.J., Volpe J.J., Jensen F.E. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia. J. Neurosci. 2008, 28:6670-6678.
22. McDonald J.W., Silverstein F.S., Johnston M.V. MK-801 pretreatment enhances N-methyl-d-aspartate-mediated brain injury and increases brain N-methyl-d-aspartate recognition site binding in rats. Neuroscience 1990, 38:103-113.
23. Olney J.W., Young C., Wozniak D.F., Jevtovic-Todorovic V., Ikonomidou C. Do pediatric drugs cause developing neurons to commit suicide?. Trends Pharmacol. Sci. 2004, 25:135-139.
24. Olney J.W., Tenkova T., Dikranian K., Muglia L.J., Jermakowicz W.J., D'Sa C., Roth K.A. Ethanol-induced caspase-3 activation in the in vivo developing mouse brain. Neurobiol. Dis. 2002, 9:205-219.
25. Owley T., Salt J., Guter S., Grieve A., Walton L., Ayuyao N., Leventhal B.L., Cook E.H. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 2006, 16:517-524.
26. Parsons C.G., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., Krzascik P., Hartmann S., Danysz W. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995, 34:1239-1258.
27. Quinlan E.M., Olstein D.H., Bear M.F. Bidirectional, experience-dependent regulation of N-methyl-d-aspartate receptor subunit composition in the rat visual cortex during postnatal development. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:12876-12880.
28. Rammes G., Mahal B., Putzke J., Parsons C., Spielmanns P., Pestel E., Spanagel R., Zieglgansberger W., Schadrack J. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001, 40:749-760.
29. Sheng M., Cummings J., Roldan L.A., Jan Y.N., Jan L.Y. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 1994, 368:144-147.
30. Sherwood N.M., Timiras P.S. A Stereotaxic Atlas of the Developing Rat Brain 1970, Univ. of Calif. Press, Berkeley.
31. Shi S.H., Hayashi Y., Petralia R.S., Zaman S.H., Wenthold R.J., Svoboda K., Malinow R. Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science 1999, 284:1811-1816.
32. Talos D.M., Follett P.L., Folkerth R.D., Fishman R.E., Trachtenberg F.L., Volpe J.J., Jensen F.E. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury II. Human cerebral white matter and cortex. J. Comp. Neurol. 2006, 497:61-77.
33. Talos D.M., Fishman R.E., Park H., Folkerth R.D., Follett P.L., Volpe J.J., Jensen F.E. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. I. Rodent cerebral white matter and cortex. J. Comp. Neurol. 2006, 497:42-60.
34. Thomas S.J., Grossberg G.T. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin. Interv. Aging 2009, 4:367-377.
35. Volpe J.J. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol. 2009, 8:110-124.
36. Wang D.D., Kriegstein A.R. GABA regulates excitatory synapse formation in the neocortex via NMDA receptor activation. J. Neurosci. 2008, 28:5547-5558.
37. Wenthold R.J., Yokotani N., Doi K., Wada K. Immunochemical characterization of the non-NMDA glutamate receptor using subunit-specific antibodies. J. Biol. Chem. 1992, 267(1):501-507.
38. Williams K., Russell S.L., Shen Y.M., Molinoff P.B. Developmental switch in the expression of NMDA receptors occurs in vivo and in vitro. Neuron 1993, 10:267-278.
39. Wilson M.A., Kinsman S.L., Johnston M.V. Expression of NMDA receptor subunit mRNA after MK-801 treatment in neonatal rats. Brain Res. Dev. Brain Res. 1998, 109:211-220.
40. Yashiro K., Philpot B.D. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 2008, 55:1081-1094.
41. Young C., Jevtovic-Todorovic V., Qin Y.Q., Tenkova T., Wang H., Labruyere J., Olney J.W. Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain. Br. J. Pharmacol. 2005, 146:189-197.
42. Zou X., Patterson T.A., Divine R.L., Sadovova N., Zhang X., Hanig J.P., Paule M.G., Slikker W., Wang C. Prolonged exposure to ketamine increases neurodegeneration in the developing monkey brain. Int. J. Dev. Neurosci. 2009, 27:727-731.